Guideline on good pharmacovigilance practices (GVP) Module X – Additional monitoring:
Introduction:
Pharmacovigilance is a vital public health function with the aim of rapidly detecting and responding to potential safety hazards associated with the use of medicinal products.
A medicinal product is authorised on the basis that, its benefit-risk balance is considered to be positive at that time for a specified target population within its approved indication (s). However, not all risks can be identified at the time of initial authorisation and some of the risks associated with the use of a medicinal product emerge or are further characterised in the post-authorisation phase of the product’s lifecycle. . To strengthen the safety monitoring of medicinal products, the 2010 EU Pharmacovigilance legislation, further amended in 2012, has introduced a framework for enhanced risk proportionate post-authorisation data collection for medicinal products, including the concept of additional monitoring for certain medicinal products.
Click on the titles below for complete guidelines
Table of contents
X.B.1. Principles for assigning additional monitoring status to a
medicinal product
X.B.2. Communication and transparency
X.C. Operation of the EU network
X.C.1. Criteria for including a medicinal product in the additional
monitoring list
X.C.3. Roles and responsibilities
X.C.3.1. The European Commission
X.C.3.3. National competent authorities
X.C.3.4. The Pharmacovigilance Risk Assessment Committee (PRAC)
X.C.3.5. The Marketing authorisation holder
X.C.4. Creation and maintenance of the list
X.C.4.1. Process for the creation of the list
X.C.4.2. Process for the maintenance of the list
X.C.4.2.1. Inclusion of medicinal products in the list
EMA GVP Module 10:
